XtalPi has signed an MoU with South Korea’s Dong-A ST to co-develop novel therapies for immunological and inflammatory diseases using its AI-driven, automated drug discovery platform.
John Wang | 20/08/2025 | By Mrinmoy Dey | 127
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy